PHENERGAN (promethazine hydrochloride) by Teva is clinical pharmacology promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. First approved in 1960.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PHENERGAN (promethazine hydrochloride) is a first-generation phenothiazine derivative approved in 1960 that functions as an H1 receptor antagonist with clinically useful sedative and antiemetic properties. It is used to manage allergic reactions, nausea/vomiting, and sedation across multiple routes of administration including rectal suppository formulation. The drug works by blocking histamine receptors while exhibiting minimal dopamine antagonism compared to other phenothiazines, with effects apparent within 20 minutes and lasting 4–12 hours.
Legacy product in decline with minimal linked job opportunities; brand teams likely focused on maintaining market position and managing generic conversion.
CLINICAL PHARMACOLOGY Promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. It is thought that this configuration is responsible for its relative lack (1/10 that of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PHENERGAN represents a legacy brand with minimal career growth potential; roles are primarily defensive, focused on generic management and maintaining existing market share rather than driving innovation or expansion. Assignment to this product is typically an entry-level or transitional role, with limited visibility and advancement opportunities compared to growth-stage brands.
Worked on PHENERGAN at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo